Antidepressant drug use & the risk of suicide

International Review of Psychiatry

Volumn 17, Issue 3, 2005, Pages 163-172

  Healy, David ^a   Aldred, Graham ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; CITALOPRAM; FLUOXETINE; FLUVOXAMINE; MIRTAZAPINE; NEFAZODONE; PAROXETINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ACCURACY; CALCULATION; CLINICAL TRIAL; DATA BASE; DEPRESSION; DRUG UPTAKE; DRUG USE; EVIDENCE BASED MEDICINE; FOOD AND DRUG ADMINISTRATION; HUMAN; INCIDENCE; MATHEMATICAL MODEL; POSTMARKETING SURVEILLANCE; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SUICIDAL BEHAVIOR; UNITED KINGDOM;

ANTIDEPRESSIVE AGENTS; DEPRESSION; DRUG THERAPY; HUMANS; INCIDENCE; RISK FACTORS; SUICIDE;

EID: 20444474608     PISSN: 09540261     EISSN: None     Source Type: Journal    
DOI: 10.1080/09540260500071624     Document Type: Review

References (24)

1. Boardman, A. P., & Healy, D. (2001). Modeling suicide risk in primary care primary affective disorders. European Psychiatry, 16, 400-405.
2. Baldwin, D. (1993). The treatment of recurrent brief depressive disorders. European College of Neuropsychopharmacology Meeting, 19 September, London.
3. Didham, R., McConnell, D. W., Blair, H. J., & Reith, D. M. (subm.). Suicide and self-harm following prescription of SSRIs and other antidepressants. British Journal of Clinical Pharmacology.
4. FDA (2004). Presentation of data from Jick et al., JAMA study presented by Diane Woolfson at Meeting of the Psychopharmacologic Drugs Advisory Committee with the Pediatric Sub-Committee of the Anti-Infective Drugs Advisory Committee. 13-14 September 2004.
5. Fergusson, D., Doucette, S., Cranley-Glass, K., Shapiro, S., Healy, D., Hebert, P., et al. (2005). The association between suicide attempts and SSRIs: A systematic review of 677 randomized controlled trial representing 85,470 participants. BMJ, 330, 376-399.
6. Glaxo SmithKline (2003). Data on file. Important safety information regarding paxil in pediatric patients. Glaxo SmithKline, Therapeutic Products Directorate: TDP-Web, 18th July 2003. Health Canada, www.hc-sc.gc.ca/hpfb-dgpsa/ tpd-dpt/paxil_pa_e.html.
7. Gunnell, D., & Ashby, D. (2004). Antidepressants and suicide: What is the balance of benefit and harm. British Medical Journal, 329, 34-38.
8. Hagnell, O., Lanke, J., & Rorsman, B. (1981). Suicide rates in the Lundby study: Mental illness as a risk factor for suicide. Neuropsychobiology, 7, 248-253.
9. Hammad, T. A., Mosholder, A., Boehm, G., Racoosin, J. A., & Laughren, T. (2003). Incidence of suicides in randomized controlled trials of patients with major depressive disorder. Pharmacoepidemiology & Drug Safety, 72(Suppl 1), S156.
10. Healy, D., & Whitaker, C. J. (2003). Antidepressants and suicide: risk benefit conundrums. Journal of Psychiatry & Neuroscience, 28, 331-339.
11. Jick, S., Dean, A. D., & Jick, H. (1995). Antidepressants and suicide. British Medical Journal, 310, 215-218.
12. Jick, H. S., Kaye, J. A., & Jick, S. (2004). Antidepressants and the risk of suicidal behaviors. Journal of the American Medical Association, 292, 338-342.
13. Khan, A., Warner, H. A., & Brown, W. A. (2000). Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials. Archives General Psychiatry, 57, 311-317.
14. Khan, A., Khan, S., Kolts, R., & Brown, W. A. (2003). Suicide rates in clinical trials of SSRIs, other antidepressants, and placebo: analysis of FDA reports. American Journal of Psychiatry, 160, 790-792.
15. Kielholz, P., & Battegay, R. (1958). Behandlung depressiver Zustandsbilder, unter spezieller Berücksichtigung von Tofranil, einem neuen Antidepressivum. Schweiz Med Wochenschrift, 88, 763-767.
16. Kieholz, P. (1971). Diagnose und Therapie der Depressionen fur Praktiker. J F Lehmanns, Munchen.
17. Laughren, T. (2004). Team Leader, Psychiatric Drugs Products Group, FDA. Presented at FDA Advisory Committee Meeting, 2nd February 2004.
18. MacKay, F. J., Dunn, N. R., Wilton, L. V., Pearce, G. L., Freemantle, S. N., & Mann, R. D. (1997). A comparison of fluvoxamine, fluoxetine, sertraline and paroxetine examined by observational cohort studies. Pharmacoepidemiology & Drug Safely, 6(Suppl 3), 235-246.
19. Montgomery, D. B., Roberts, A., Green, M., Bullock, T., Baldwin, D., & Montgomery, S. A. (1994). Lack of efficacy of fluoxetine in recurrent brief depression and suicidal attempts. European Archives of Psychiatry & Clinical Neuroscience, 244, 211-215.
20. Montgomery, S. A., Dunner, D. L., & Dunbar, G. (1995). Reduction of suicidal thoughts with paroxetine in comparison to reference antidepressants and placebo. European Neuropsychopharmacology, 5, 5-13.
21. Simon, G. E., & VonKorff, M. (1998). Suicide mortality among patients treated for depression in an insured population. American Journal of Epidemiology, 147, 155-160.
22. Storosum, J. G., van Zwieten B. J., van den Brink, W., Gersons, B. P., & Broekman, A. W. (2001). Suicide rate in placebo controlled studies of major depression. American Journal of Psychiatry, 158, 1271-1275.
23. Teicher, M. H., Glod, C., & Cole, J. O. (1990). Emergence of intense suicidal preoccupation during fluoxetine treatment. American Journal of Psychiatry, 147, 207-210.
24. Weel-Baumgarten, E., van Den Bosch, W., van Den Hoogen, H., & van Zitman, F. G. (1998). Ten year follow up of depression after diagnosis in general practice. British Journal of General Practice, 48, 1643-1646.